Journal article

Publication year: 2005

Pages: 545-551

Journal: Journal of Veterinary Pharmacology and Therapeutics

Volume number: 28

Issue number: 6

ISSN: 0140-7783

eISSN: 1365-2885

DOI Link: https://doi.org/10.1111/j.1365-2885.2005.00692.x

Publisher: Wiley

Abstract: 
MDR1 (ABCB1) P-glycoprotein exerts a protective function in the blood-brain barrier thereby limiting the entry of many drugs and other xenobiotics to the central nervous system. A nonsense mutation has been described for Collies and related dog breeds which abolishes this function and is associated with increased susceptibility to neurotoxic side effects of several drugs including ivermectin, moxidectin and loperamide. In order to evaluate the occurrence and frequency of this nt230 (del4) MDR1 mutation in Germany, we screened 1500 dogs. Frequency of the homozygous mutated genotype was highest for Collies (33.0%), followed by Australian Shepherd (6.9%) and Shetland Sheepdog (5.7%). Thirty-seven percent of the Waller dogs and 12.5% of the Old English Sheepdogs were heterozygous for the mutant MDR1 (-) allele. Considering the predominant role of MDR1 P-glycoprotein in drug disposition and in particular for blood-brain barrier protection, MDR1 genotype-based breeding programs are recommended for improving the safety of drug therapy in these canine breeds.

Harvard Citation style: Geyer, J., Döring, B., Godoy, J., Leidolf, R., Moritz, A. and Petzinger, E. (2005) Frequency of the nt230 (del4) MDR1 mutation in Collies and related dog breeds in Germany, Journal of Veterinary Pharmacology and Therapeutics, 28(6), pp. 545-551. https://doi.org/10.1111/j.1365-2885.2005.00692.x

APA Citation style: Geyer, J., Döring, B., Godoy, J., Leidolf, R., Moritz, A., & Petzinger, E. (2005). Frequency of the nt230 (del4) MDR1 mutation in Collies and related dog breeds in Germany. Journal of Veterinary Pharmacology and Therapeutics. 28(6), 545-551. https://doi.org/10.1111/j.1365-2885.2005.00692.x